Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07617597
PHASE3

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

Sponsor: Sun Pharma Japan Limited

View on ClinicalTrials.gov

Summary

This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.

Official title: A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

78

Start Date

2026-06-19

Completion Date

2028-09

Last Updated

2026-07-02

Healthy Volunteers

No

Conditions

Interventions

DRUG

Deuruxolitinib

Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg

DRUG

Placebo

Deuruxolitinib matching placebo will be dosed orally as tablets for up to 24 weeks and then deuruxolitinib will be dosed for up to 52 weeks

Locations (18)

Study Site 102

Asahikawa, Japan

Study Site 117

Bunkyō City, Japan

Study Site 119

Ebina, Japan

Study Site 101

Hamamatsu, Japan

Study Site 116

Ishikawa, Japan

Study Site 112

Kitakyushu, Japan

Study Site 118

Kōtoku, Japan

Study Site 110

Kurashiki, Japan

Study Site 113

Kurume, Japan

Study Site 107

Kyoto, Japan

Study Site 106

Mitaka-shi, Japan

Study Site 114

Miyagi-gun, Japan

Study Site 104

Niigata, Japan

Study Site 109

Osaka, Japan

Study Site 108

Osaka, Japan

Study Site 103

Sapporo, Japan

Study Site 105

Shinjuku-Ku, Japan

Study Site 111

Ube, Japan